雑誌
- 我が国の特発性心筋症診療における遺伝子診断の認識と現況.
大谷朋仁, 安井治代, 坂田泰史.
心臓、57(5)、pp.459-466.
- Shortening and optimization of MEF2C and GATA4 promote cardiac reprogramming.
Honda S, Sadahiro T, Abe Y, Yamada Y, Akiyama T, Nakano K, Umei TC, Nakamura M, Maeda T, Okada H, Hayashi Y, Ishizu T, Ieda M .
Biochem Biophys Res Commun. 781: 152511.
- Response by Yamada et al to Letter Regarding Article, "Cardiac Reprogramming and Gata4 Overexpression Reduce Fibrosis and Improve Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction".
Yamada Y, Sadahiro T, Ieda M .
Circulation. 152(18): pp. 1320-1321.
- Contemporary clinical characteristics and management patterns in hypertrophic cardiomyopathy: insights from baseline enrolment data in a nationwide prospective Japanese registry.
Kubo T, Sugiura K, Tokita Y, Takano H, Takamisawa I, Takayama M, Doi YL, Minami Y, Shirotani S, Ebato M, Tsujiuchi M, Nabeta T, Inomata T, Kato T, Okamoto R, Dohi K, Takei Y, Chikamori T, Watanabe E, Furugen A, Doi H, Akita K, Maekawa Y, Ogimoto A, Tada N, Yokota T, Ikeda S, Yamaguchi O, Izumiya Y, Shibata A, Takashio S, Tsujita K, Maejima Y, Fujino N, Nomura A, Akasaki Y, Higuchi K, Fujita S, Hoshiga M, Shiraishi Y, Ieda M, Miyamoto Y, Kitaoka H.
Heart. 111(18): pp. 885-892.
- Prefectural Survey on Immune Checkpoint Inhibitor-Associated Myocarditis at the Start of the Basic Plan to Promote Cancer Control Programs - Phase 4.
Okura Y, Miura S, Tanabe N, Ozaki K, Kashimura T, Kikuchi A, Takenouchi T, Tanaka H, Saijo Y, Inomata T; OCAN 2020 Collaborators.
Circ Rep. 7(3): pp. 176-182.
- Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: From Sarcomere to Clinic.
Nakamura K, Okumura T, Kato S, Onoue K, Kubo T, Kouzu H, Yano T, Inomata T.
Int J Mol Sci. 26(19): 9347.
- JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure.
Kitai T, Kohsaka S, Kato T, Kato E, Sato K, Teramoto K, Yaku H, Akiyama E, Ando M, Izumi C, Ide T, Iwasaki YK, Ohno Y, Okumura T, Ozasa N, Kaji S, Kashimura T, Kitaoka H, Kinugasa Y, Kinugawa S, Toda K, Nagai T, Nakamura M, Hikoso S, Minamisawa M, Wakasa S, Anchi Y, Oishi S, Okada A, Obokata M, Kagiyama N, Kato NP, Kohno T, Sato T, Shiraishi Y, Tamaki Y, Tamura Y, Nagao K, Nagatomo Y, Nakamura N, Nochioka K, Nomura A, Nomura S, Horiuchi Y, Mizuno A, Murai R, Inomata T, Kuwahara K, Sakata Y, Tsutsui H, Kinugawa K; Japanese Circulation Society and the Japanese Heart Failure Society Joint Working Group.
J Card Fail. 31(8): pp. 1164-1322.
- The use of left ventricular ejection fraction in the diagnosis and management of heart failure. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC, the Heart Failure Society of America (HFSA), and the Japanese Heart Failure Society (JHFS).
Rosano GMC, Teerlink JR, Kinugawa K, Bayes-Genis A, Chioncel O, Fang J, Greenberg B, Ibrahim NE, Imamura T, Inomata T, Kuwahara K, Moura B, Onwuanyi A, Sato N, Savarese G, Sakata Y, Sweitzer N, Wilcox J, Yamamoto K, Metra M, Coats AJS.
Eur J Heart Fail. 27(7): pp. 1174-1187.
- 2023 Update of the Japanese Heart Failure Society Scientific Statement on BNP and NT-proBNP levels in Heart Failure Practice.
Minamisawa M, Anzai T, Inomata T, Kinugawa K, Sakata Y, Sato N, Tsutsui H, Yamamoto K, Yoshimura M, Saito Y, Kuwahara K.
J Card Fail. 31(9): pp. 1453-1459.
- Urocortin2 measurement for heart failure assessment.
Inukai K, Miyashita K, Kotani K, Morimoto R, Kondo T, Hiraiwa H, Kazama S, Yoshida T, Yoshida S, Hattori T, Fukamachi K, Fukui N, Kato K, Yura Y, Ohashi K, Ouchi N, Murohara T, Okumura T, Takefuji M.
Sci Rep. 15(1): 14381.
- Clinical utility of dynamic chest radiography as an auxiliary tool for atrial fibrillation detection in heart failure: a pilot study.
Hiraiwa H, Nagai S, Ito R, Kondo K, Kazama S, Kondo T, Adachi S, Furusawa K, Tanaka A, Morimoto R, Okumura T, Murohara T.
BMC Cardiovasc Disord. 25(1): p. 381.
- Prognostic value of symptom burden as a simple patient-reported outcome measure in older patients with heart failure.
Tanaka S, Imaizumi T, Morohashi A, Kobayashi K, Takagi D, Hattori K, Yoshito N, Takeuchi S, Tsuchikawa Y, Inoue T, Nagaya M, Nishida Y, Morimoto R, Kondo T, Hiraiwa H, Kazama S, Okumura T, Murohara T.
Sci Rep. 15(1): 22954.
- Integrative Transcriptomic-Histological Analysis in Dilated Cardiomyopathy Unveils FGFR1 Inhibition as Anti-Cardiac Fibrotic and Cardioprotective Therapy .
Hata R, Funakoshi S, Makiyama T, Kato T, Narita M, Matsumura Y, Hirohata R, Naka Y, Ida K, Ito H, Yoshizawa A, Nannya Y, Haga H, Ogawa S, Ono K, Kimura T, Yoshida Y.
JACC Basic Transl Sci. 10(10): 101363.
- Precision cardiology: Integrating gene therapy, genome editing, and single-cell genomics.
Nishino T, Ono K.
J Cardiol. 87(2): pp.121-127.
- Critical Role of microRNA-33a/b in Cardiovascular and Metabolic Disease: Molecular Mechanisms and Therapeutic Perspectives.
Horie T, Baba O, Nishino T, Yamashita Y, Tsujisaka Y, Ono K.
J Atheroscler Thromb. 33(1): pp. 13-19.
- Validation of Guideline Recommendation on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy.
Amano M, Kitaoka H, Yoshikawa Y, Sakata Y, Dohi K, Tokita Y, Kato T, Matsushima S, Kitai T, Okada A, Furukawa Y, Tamura T, Hayashida A, Abe H, Ando K, Yuda S, Inoko M, Kadota K, Abe Y, Iwakura K, Kitamura T, Masuda J, Ohara T, Omura T, Tanigawa T, Nakamura K, Nishimura K, Izumi C; REVEAL-HCM Investigators.
JACC Heart Fail. 13(6): pp. 1014-1026.
- Validation of the 2018 Japanese Circulation Society (JCS)/Japanese Heart Failure Society (JHFS) Guidelines for Preventing Sudden Cardiac Death in Patients With Hypertrophic Cardiomyopathy.
Amano M, Kitaoka H, Yoshikawa Y, Kubo T, Sakata Y, Dohi K, Tokita Y, Kato T, Matsushima S, Kitai T, Okada A, Furukawa Y, Tamura T, Hayashida A, Abe H, Ando K, Yuda S, Inoko M, Kadota K, Abe Y, Iwakura K, Kitamura T, Masuda J, Ohara T, Omura T, Tanigawa T, Nakamura K, Nishimura K, Izumi C; REVEAL-HCM Investigators.
Circ J. 90(2): pp. 162-170.
- Prognostic Implications of Mitral Regurgitation Across Hypertrophic Cardiomyopathy Subtypes: A Report From REVEAL-HCM Study.
Obayashi Y, Kato T, Shiomi H, Nakatsuka K, Kitaoka H, Sakata Y, Dohi K, Tokita Y, Matsushima S, Amano M, Furukawa Y, Tamura T, Hayashida A, Abe H, Ando K, Yuda S, Inoko M, Ono K, Nishimura K, Izumi C; REVEAL-HCM Investigators.
Circ Heart Fail. 19: e013977.
- Usefulness of exercise stress echocardiography for predicting cardiovascular events and atrial fibrillation in hypertrophic cardiomyopathy.
Yoshii T, Amano M, Moriuchi K, Nakagawa S, Nishimura H, Tamai Y, Mizumoto A, Koda A, Demura Y, Jo Y, Irie Y, Sakamoto T, Amaki M, Kanzaki H, Noguchi T, Nishimura K, Kitai T, Izumi C.
J Cardiol. 85(4): pp. 321-328.
- Tenascin-C and Fibrosis as Prognostic Predictors of Peripartum Cardiomyopathy - A Histopathological Study.
Amemiya K, Nakashima J, Ohta-Ogo K, Ishibashi-Ueda H, Matsumoto M, Ikeda Y, Morita Y, Tsukamoto Y, Yoshimatsu J, Hatakeyama K, Aoki-Kamiya C.
Circ J. Online ahead of print.
- 周産期心筋症 Peripartum Cardiomyopathy.
神谷千津子.
日本産科婦人科学会雑誌、77(12)、pp. 1796-1801.
- 周産期心筋症のレビュー −概説、周産期管理と次回妊娠予後について−.
手向麻衣, 神谷千津子, 吉松淳.
産婦人科の実際、74(4)、pp. 409-419.
- Guideline-directed medical therapy and hypotension after initiation of vericiguat: Insights from the VERIFY-HF study.
Kanaoka K, Nakoji T, Takegawa K, Ishihara S, Nasu T, Fujimoto W, Kagiyama N, Shiraishi Y, Ishii S, Ijichi T, Nakazawa G, Iwanaga Y, Hikoso S, Miyamoto Y, Matsumoto S.
J Cardiol. S0914-5087z(26): 00062-6.
- Apolipoprotein A-IV Cardiac Amyloidosis Diagnosed by Mass Spectrometry-Based Proteomic Analysis.
Masutani Y, Onoue K, Soeda T, Nakano T, Sakaguchi Y, Endo J, Shintani-Domoto Y, Kanamori H, Kametani F, Hikoso S, Kawata H.
JACC Case Rep. 31(15): 107355.
- Prognostic Impact of Combined Nutritional and Cognitive Status on Long-Term Outcome in Acute Decompensated Heart Failure.
Nogi K, Ueda T, Kyodo A, Ishihara S, Nakada Y, Hashimoto Y, Nakagawa H, Nishida T, Seno A, Onoue K, Watanabe M, Saito Y, Hikoso S.
Nutrients. 18(2): p. 189.
- Prognostic Value of In-Hospital Nutritional Status Improvement in Heart Fyailure: Insights From JROADHF-NEXT Registry .
Okabe T, Kida K, Enzan N, Ikeda M, Okumura T, Kitai T, Tohyama T, Taniguchi T, Matsushima S, Matsue Y, Tsutsui H.
Glob Heart. 21(1): p. 20.
- Frailty Scale Captures Multidimensional Vulnerability and Predicts Mortality in Heart Failure.
Nakade T, Fujimoto Y, Singh YS, Akama Y, Ide T, Kida K, Matsushima S, Kaku H, Enzan N, Ikeda M, Kitai T, Taniguchi T, Okumura T, Tohyama T, Tsutsui H, Matsue Y.
J Am Coll Cardiol. 87(1): pp. 20-32.
- Clinical characteristics and outcomes of hospitalized patients with heart failure from the Japanese prospective registry.
Enzan N, Tohyama T, Watanabe T, Nagata T, Noda E, Tsutsui Y, Ikeda M, Sakamoto T, Matsushima S, Matsue Y, Kitai T, Taniguchi T, Kida K, Okumura T, Kishi T, Ide T, Tsutsui H.
J Cardiol. 87(1): pp. 85-91.
書籍
- 「拡張型・肥大型心筋症の『心不全リスク』をどう評価する？」奥村貴裕．
『月刊 薬事』、pp. 32-37、2025年9月．
- 「その他の治療（妊娠期）」神谷千津子．
『心不全療養指導士認定試験ガイドブック改訂第3版』、pp. 118-121、2026年3月．
- 「序文」筒井裕之．
『患者管理を支える心不全チーム医療のためのDestination Therapy教本』、p.257、2025年3月．